Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

NCT06226545 is registered in ClinicalTrials.gov with Lassen Therapeutics Inc. as lead sponsor.

NCT NCT06226545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06226545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Lead sponsor
Lassen Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2024
Completion date
April 22, 2025
Enrollment
41 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, eye diseases, graves ophthalmopathy, graves orbitopathy, orbital diseases, proptosis, thyroid associated ophthalmopathy, thyroid eye disease